Logo-jcvtr
Submitted: 02 Mar 2024
Revision: 06 Jan 2025
Accepted: 27 Feb 2025
ePublished: 18 Mar 2025
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

J Cardiovasc Thorac Res. 2025;17(1): 58-65.
doi: 10.34172/jcvtr.025.33123
Plum Print visual indicator of research metrics
  • Captures
    • Readers: 3
  • Mentions
    • News Mentions: 1
see details
  Abstract View: 339
  PDF Download: 300
  Full Text View: 24

Original Article

Safety and efficacy of Evermine50 Everolimus-eluting coronary stent system in patients with native coronary artery lesions: Three-year outcomes from a single-center

Suresh V Patted 1* ORCID logo

1 Department of Cardiology, KLE Academy of Higher Education & Research, Belagavi, Karnataka, India
*Corresponding Author: Suresh V Patted, Email: drpatted@yahoo.com

Abstract

Introduction: The Evermine50™ (Meril Life Sciences Pvt. Ltd., India) is the world’s thinnest strut (50 µm) featuring a biodegradable polymer-based Everolimus-eluting stent (EES) system. We present the 3-year safety and performance outcomes of Evermine50 EES.

Methods: This was a prospective, post-marketing, single-center study of patients with native coronary artery lesions (CAL) in real-world settings. Patients with symptomatic ischemic heart disease due to de novo and in-stent restenotic lesions (lengths<44mm) in native coronary arteries with reference vessel diameters of 2.0 - 4.5 mm. and eligible for stenting procedure with percutaneous transluminal coronary angioplasty were included.

Results: A total of 251 patients (mean age: 58.20 years) were enrolled, of which 48.2% had ST-elevation myocardial infarction and 31.5% had silent ischemia. The mean lesion length was 21.81±8.14 mm, and 70.3% of patients had pre-procedure Thrombolysis in Myocardial Infarction (TIMI) flow grade III. The average and stent length was recorded as 23.50±12.21 mm. In 98% of patients, post-procedural TIMI-III flow grade was achieved. The cumulative rate of major adverse cardiac events defined as composite of cardiac death, target vessel myocardial infarction, and clinically-driven target lesion revascularization (CD-TLR) at 1, 2, and 3 years were 1.59%, 3.58%, and 3.58%, respectively. The cumulative rates of CD-TLR remained constant at 0.79% from 1 to 3 years. There were no cases of stent thrombosis until 3 years.

Conclusion: This study demonstrated favorable safety and performance of the ultrathin Evermine50 EES at 36 months in patients with native CAL.


Captures
  • Readers: 3
Mentions
  • News Mentions: 1
First Name
Last Name
Email Address
Comments
Security code


Abstract View: 340

Your browser does not support the canvas element.


PDF Download: 300

Your browser does not support the canvas element.


Full Text View: 24

Your browser does not support the canvas element.